Pfizer, BioNTech Publish “Encouraging” Interim Phase I/II Data for COVID-19 Vaccine Construct

Pfizer and BioNTech said the most advanced of four constructs of their messenger RNA (mRNA) vaccine candidate for COVID-19 showed encouraging immunogenicity and a favorable safety profile in preliminary Phase I/II data published in a preprint study.

Read the full article here

Related Articles